TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02534012

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Major abdominal surgery
Study: NCT01415297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKP-1339
Description: NKP-1339 is administered as a 30-90 minute IV infusion (based on volume to be infused) on days 1, 8, and 15 of a 28 day cycle.
Study: NCT01301053

Intervention type: OTHER
Group type: OTHER
Intervention: Current UVA intensive care insulin protocol
Description: Current UVA intensive care insulin protocol used for insulin management for 12 hours

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Current UVA intensive care insulin protocol with brakes
Description: Current UVA intensive care insulin protocol for insulin management with the addition of brakes which reduces insulin administration based on continuous glucose monitoring data between hourly reference glucose data to reduce episodes of hypoglycemia (blood glucose \<70 mg/dl)and severe hypoglycemia (blood glucose\<50 mg/dl).
Study: NCT04539054

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ENGN Shred
Description: ENGN Shred is a multi-ingredient pre-workout supplement.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutricost caffeine powder
Description: Caffeine powder.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Crystal Light
Description: Non-caloric Crystal Light matched for the pre-workout in terms of flavor and consistency.
Study: NCT05645237

Intervention type: RADIATION
Intervention: radiotherapy
Description: Radiotherapy is delivered with linear accelerators or cyberknife (external beam radiotherapy), or local irradiation with high dose rate brachytherapy (brachytherapy)
Study: NCT02794883

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative Studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative Studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative Studies

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Procedure
Description: Undergo surgical tumor resection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Procedure
Description: Undergo surgical tumor resection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Procedure
Description: Undergo surgical tumor resection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tremelimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Given IV
Study: NCT05645237

Intervention type: RADIATION
Intervention: radiotherapy
Description: Radiotherapy is delivered with linear accelerators or cyberknife (external beam radiotherapy), or local irradiation with high dose rate brachytherapy (brachytherapy)

Intervention type: RADIATION
Intervention: radiotherapy
Description: Radiotherapy is delivered with linear accelerators or cyberknife (external beam radiotherapy), or local irradiation with high dose rate brachytherapy (brachytherapy)

Intervention type: RADIATION
Intervention: radiotherapy
Description: Radiotherapy is delivered with linear accelerators or cyberknife (external beam radiotherapy), or local irradiation with high dose rate brachytherapy (brachytherapy)

Intervention type: RADIATION
Intervention: radiotherapy
Description: Radiotherapy is delivered with linear accelerators or cyberknife (external beam radiotherapy), or local irradiation with high dose rate brachytherapy (brachytherapy)

Intervention type: RADIATION
Intervention: radiotherapy
Description: Radiotherapy is delivered with linear accelerators or cyberknife (external beam radiotherapy), or local irradiation with high dose rate brachytherapy (brachytherapy)
Study: NCT03035864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhNGF
Description: Eye Drop 20 μg/mL

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle Eye Drop
Study: NCT02578134

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: US-guided percutaneous electrolysis
Description: US-guided percutaneous electrolysis consists of the application of a galvanic electrical current with an acupuncture needle in the soft tissue, in this case the symptomatic insertion of the plantar fascia

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham US-guided percutaneous electrolysis
Description: The acupuncture needle will be inserted into the symptomatic plantar fascia but no galvanic electrical current will be applied, the equipment will be turn off. Patients will be blinded to the application of galvanic electrical current.
Study: NCT03996681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylcantharidimide tablets
Description: Drug: methylcantharidimide tablets~Methylcantharidimide is a single molecule drug used for the treatment of primary liver cancer.~Procedure: TACE~Transcatheter arterial chemoembolization was performed by the injection of small embolic particles coated with chemotherapeutic agents selectively into an artery directly supplying a tumor.
Study: NCT03271242

Intervention type: OTHER
Intervention: Systematic implementation support
Description: Implementation support is offered by implementation trainers visiting each clinical unit every two weeks for 6 months and then monthly for 12 months. Support is given only for the practice randomly assigned to support. The aim is to engage leaders and clinicians in identifying and overcoming implementation barriers, and in building systems to support and sustain implementation. Implementation trainers from all sites are trained together and meet every 2-3 month with leaders of the implementation training for supervision, mutual discussion, and exchange of experiences. At the start of the implementation, leaders and clinicians were also invited to a workshop on the practice they have been randomly assigned to receive support for. Toolkits are made available on a website.

Intervention type: OTHER
Intervention: No implementation support
Description: No implementation support is offered to clinical units for the practice randomly assigned to no implementation support, of the two practices (of the four practices in the project) that unit has chosen to implement.
Study: NCT00935506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Tablets, Oral, 75 mg, Once daily, 8 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Tablets, Oral, 325 mg, Once daily, 8 days
Study: NCT01894763

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Self-expandable metal stent
Description: Placement of a self-expandable metal stent in the esophagus
Study: NCT02552771

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mitral repair with leaflet preservation
Description: Placing man-made fibers (sutures) to more securely connect the mitral leaflets to the papillary muscles (muscles located in the ventricle).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mitral repair with leaflet resection
Description: Removing one or both of the mitral leaflets that flop or bulge back.
Study: NCT00303732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001 (everolimus)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTK787 (vatalanib)
Study: NCT03256097

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XDP sound processing strategy - Period 0
Description: XDP is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XDP sound processing strategy - Period 0
Description: XDP is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend.
Study: NCT00533910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: 550mg BID rifaximin for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: same as the experimental arm
Study: NCT03256097

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XDP sound processing strategy - Period 1
Description: XDP is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VG sound processing strategy - Period 1
Description: Voice Guard is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XDP sound processing strategy - Period 2
Description: XDP is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VG sound processing strategy - Period 2
Description: Voice Guard is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XDP sound processing strategy - Period 3
Description: XDP is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VG sound processing strategy - Period 3
Description: Voice Guard is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Voice Track
Description: Voice Track is a cochlear implant noise cancellation system which is designed to reduce the adverse effect of background noise on speech perception through cochlear implants
Study: NCT04334512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Treatment with hydroxychloroquine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Treatment with azithromycin

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin C
Description: Treatment with vitamin C

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Treatment with vitamin C

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D
Description: Treatment with vitamin D

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Treatment with vitamin D

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Zinc
Description: Treatment with Zinc

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc
Description: Treatment with Zinc
Study: NCT04549415

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Hydrochloride
Description: patients were divided into 2 groups: 1st group was on lifestyle modification (LSM), 2nd group on regimen LSM+ metformin (1000 g b.i.d) during 12 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: lifestyle modification
Description: Lifestyle modification Standard Principles
Study: NCT03979872

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MC1R Genetic Testing
Description: \[See arm/group descriptions\]

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MC1R Genetic Testing
Description: \[See arm/group descriptions\]

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Skin Cancer Education
Description: \[See arm/group descriptions\]
Study: NCT02129283

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simulation training
Description: End-of-life simulation training. The simulation training will include training with standardized patients (actors) using 9 essential skills for communication and interpersonal relationships. The control group will have no training.
Study: NCT04625231

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Shared-Decision Making Tool
Description: Patients received a short video presentation on pain management, use of over the counter medication, side effects of opioids and over-the-counter medications and ability to choose the amount of opioid pills up to the standard care amount.
Study: NCT01327664

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIN457
Study: NCT01119313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS 41002
Description: LAS 41002, once daily
Study: NCT03979872

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin Cancer Education
Description: \[See arm/group descriptions\]

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin Cancer Education
Description: \[See arm/group descriptions\]

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin Cancer Education
Description: \[See arm/group descriptions\]

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UV Photo
Description: \[See arm/group descriptions\]

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UV Photo
Description: \[See arm/group descriptions\]
Study: NCT03347617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo ferumoxytol MRI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT01069367

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Emulsion, Cell Culture-based, influenza HA vaccine H1N1
Description: Cell-derived A/H1N1 influenza HA vaccine (0.25 mL as injection volume)
Study: NCT01827241

Intervention type: OTHER
Intervention: Chart Review
Description: Retrospective and prospective data review of colonoscopy procedures, examination findings, resection techniques, and pathology reports.
Study: NCT02957474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GED-0301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GED-0301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GED-0301
Study: NCT01119313

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active
Description: Active, once daily
Study: NCT01217905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7687
Description: Oral suspension
Study: NCT04175405

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Irradiation of implants with 635nm laser
Description: Irradiation of implants with 635nm laser with a dose of 10J
Study: NCT03092726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8062
Description: ASP8062 30 mg was administered orally as a single daily dose, taken preferably in the morning with or without food.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was administered orally as a single daily dose, taken preferably in the morning with or without food.
Study: NCT02957474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GED-0301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Study: NCT02062242

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transvaginal electrical stimulation
Description: The current employed is biphasic and the stimulation parameters are: frequency of 50 Hz, pulse width of 200 microseconds, contraction time (Ton) of 5 seconds and relaxation time (Toff) of 10 seconds. The current intensity is defined according to the tolerance of patient and the total stimulation time is 20 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palpation
Description: The patient is positioned supine with the lower limbs bent and feet flat on the stretcher. The examiner will hold vaginal palpation and to request her the contraction of PFM. It will be requested 3 sets of 10 contractions with a rest period between contractions. There are two minutes a rest period between sets.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palpation with posterior pelvic tilt
Description: The patient is positioned supine with the lower limbs bent and feet flat on the stretcher. The examiner will hold vaginal palpation and to request her the contraction of PFM associated with posterior pelvic tilt and contraction of accessory muscles. It will be requested 3 sets of 10 contractions with a rest period between contractions. There are two minutes a rest period between sets.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: The patient receive verbal instructions related to the pelvic floor and its contraction.
Study: NCT02255760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI3902 - Dose 1
Description: Participants will receive a single IV dose of MEDI3902 infused for a minimum of 13 minutes on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI3902 - Dose 2
Description: Participants will receive a single IV dose of MEDI3902 infused for a minimum of 38 minutes on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI3902 - Dose 3
Description: Participants will receive a single IV dose of MEDI3902 infused for a minimum of 75 minutes on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI3902 - Dose 4
Description: Participants will received a single IV dose of MEDI3902 infused for a minimum of 150 minutes on Day 1.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a single dose of placebo by IV infusion up to a maximum of 12 hours.
Study: NCT02608372

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LD
Description: Participants ingested 5 g of Laminaria digitata followed by 30 g of corn starch mixed with 200 mL of water.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LD
Description: Participants ingested 5 g of Laminaria digitata followed by 30 g of corn starch mixed with 200 mL of water.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LD
Description: Participants ingested 5 g of Laminaria digitata followed by 30 g of corn starch mixed with 200 mL of water.
Study: NCT01956747

Intervention type: PROCEDURE
Intervention: venapunction

Intervention type: PROCEDURE
Intervention: bone marrow punction
Study: NCT02608372

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LD
Description: Participants ingested 5 g of Laminaria digitata followed by 30 g of corn starch mixed with 200 mL of water.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LD
Description: Participants ingested 5 g of Laminaria digitata followed by 30 g of corn starch mixed with 200 mL of water.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LD
Description: Participants ingested 5 g of Laminaria digitata followed by 30 g of corn starch mixed with 200 mL of water.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UP
Description: Participants ingested 5 g of Undaria pinnatifida followed by 30 g of corn starch mixed with 200 mL of water.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UP
Description: Participants ingested 5 g of Undaria pinnatifida followed by 30 g of corn starch mixed with 200 mL of water.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UP
Description: Participants ingested 5 g of Undaria pinnatifida followed by 30 g of corn starch mixed with 200 mL of water.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UP
Description: Participants ingested 5 g of Undaria pinnatifida followed by 30 g of corn starch mixed with 200 mL of water.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UP
Description: Participants ingested 5 g of Undaria pinnatifida followed by 30 g of corn starch mixed with 200 mL of water.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UP
Description: Participants ingested 5 g of Undaria pinnatifida followed by 30 g of corn starch mixed with 200 mL of water.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CTR
Description: Participants ingested 30 g of corn starch and 1 g of pea protein powder mixed with 200 mL of water.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CTR
Description: Participants ingested 30 g of corn starch and 1 g of pea protein powder mixed with 200 mL of water.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CTR
Description: Participants ingested 30 g of corn starch and 1 g of pea protein powder mixed with 200 mL of water.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CTR
Description: Participants ingested 30 g of corn starch and 1 g of pea protein powder mixed with 200 mL of water.
Study: NCT02574767

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling
Description: Obese pregnant women from PHCC randomized to this group will receive Home-based Diet \& Physical activity (PA) counseling. Home-based intervention will consider 2 home visits of one hour of duration. During this session dietary educational and behavioral will be discussed with the participants and their families tailoring the contents based on the specific contexts.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling
Description: Obese pregnant women from PHCC randomized to this group will receive Home-based Diet \& Physical activity (PA) counseling. Home-based intervention will consider 2 home visits of one hour of duration. During this session dietary educational and behavioral will be discussed with the participants and their families tailoring the contents based on the specific contexts.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PUFA Supplementation
Description: Obese pregnant women from PHCC randomized to this group will receive n3LC-PUFAs oral supplementation based on Schizochytrium oil (S-oil) containing 800 mg docosahexaenoic (DHA) acid/day, which will be administered as capsular preparations containing 200 mg DHA/capsule (4 capsules/day).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PUFA Supplementation
Description: Obese pregnant women from PHCC randomized to this group will receive n3LC-PUFAs oral supplementation based on Schizochytrium oil (S-oil) containing 800 mg docosahexaenoic (DHA) acid/day, which will be administered as capsular preparations containing 200 mg DHA/capsule (4 capsules/day).
Study: NCT02608372

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CTR
Description: Participants ingested 30 g of corn starch and 1 g of pea protein powder mixed with 200 mL of water.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CTR
Description: Participants ingested 30 g of corn starch and 1 g of pea protein powder mixed with 200 mL of water.